Tysabri approved for Chron’s disease
Tysabri [natalizumab] has become the third biologic medication approved for the treatment of Crohn’s disease. Unlike the other two approved biologics, Remicade [infliximab] and Humira [adalimumab], Tysabri does not work by inhibiting tumor necrosis factor (TNF). Because of this it offers an alternative biologic treatment for those patients who either cannot tolerate or who do not respond well enough to the TNF inhibitors. Instead, it binds to a protein on the surface of certain types of white blood cells and prevents them from leaving the blood stream to enter the tissues where they would otherwise cause inflammation. Tysabri has already been approved for the treatment of multiple sclerosis.
Tysabri is approved for use in adults with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are intolerant of, conventional Crohn’s therapies and TNF-inhibitors. Tysabri is given by […]
Original post by admin and weightlossopinions.com
